VivoSeq
Infectious Disease

Mpox

4

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Mpox is an early-stage landscape with 4 programs across 3 companies. The most active players are Moderna, BioNTech, GSK. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

50/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Moderna logo

Moderna

1 program

Phase 1BioNTech logo

BioNTech

1 program

Phase 2GSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

2programs
Small molecule150%
RNA therapy150%

Modality classified for 75% of 4 pipeline programs.

Analysis

Trial Status

3

clinical trials

Recruiting1 · 33%
Terminated1 · 33%
Completed1 · 33%

Clinical Trials

Trial Activity

Safety, Reactogenicity, and Immunogenicity of an Mpox mRNA Vaccine Candidate, BNT166a, in Healthy Participants Aged 18 Years and Older in African Countries: A Randomized, Double-blind, Placebo-controlled Phase II Trial
Recruiting·BioNTech logoBioNTech·Phase 2·NCT07379580·310 enrolled
A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Mpox Virus Disease
Terminated·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT05534984·719 enrolled
STOMP: Tecovirimat in Mpox Treatment
Completed·GSK logoGSK·Phase 3·NCT04661553·540 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)